Product Information
LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM is a generic product labeled by E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., priced at $1.3353 per GM under NDC 00168035755. Its NADAC has been published 472 times since Jan 22, 2014.
FDA first approved this application on Aug 18, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 25 mg/g; mg/g
NDC
00168035755
Classification
Generic
Dosage Form
CREAM
Route
TOPICAL
Effective Date
7/22/2026
Active Ingredients
LIDOCAINE; PRILOCAINEApproval Type
Generic (ANDA)
FDA Application
ANDA076453FDA Approved
8/18/2003
TE Code
AB
On Market Since
8/18/2003
Pharmacological Classes
Price Statistics
The NADAC for LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM has been published 472 times since Jan 22, 2014, and over the history we have for it it has risen 12.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3353 per GM |
|---|---|
| All-time high | $1.5054 (Dec 10, 2025) |
| All-time low | $0.5175 (Jun 19, 2019) |
| 52-week high | $1.5054 |
| 52-week low | $1.3340 |
| Median price | $0.9715 |
| Average price | $0.9727 |
| Largest weekly change | +79.0% (Jan 19, 2022) |
| Weeks tracked | 472 |
| Tracking since | Jan 22, 2014 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 83% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lidocaine and prilocaine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Amide Local Anesthetic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM?
The current National Average Drug Acquisition Cost (NADAC) for LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM, manufactured by E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., is $1.3353 per GM (NDC 00168035755), effective Sep 30, 2026.
How has the price of LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM changed over time?
Over the history we have for it, the NADAC for LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM has risen 12.8%. It has been tracked across 472 weekly CMS publications since Jan 22, 2014.
What are the highest and lowest recorded NADAC prices for LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM?
Since Jan 22, 2014, the NADAC for LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM has ranged from a low of $0.5175 (Jun 19, 2019) to a high of $1.5054 (Dec 10, 2025), with a median of $0.9715 per GM.
Are there cheaper alternatives to LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM, is $0.2317 per GM — about 83% below LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM.
Who manufactures LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM?
LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM (NDC 00168035755) is labeled by E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., and CMS classifies it as a generic product.